Rhabdomyosarcoma Market Research Report: By Type (Embryonal & Alveolar), by Diagnosis (X-Ray, CT scan, MRI, PET scan, Bone scan, Needle & Surgical Biopsy), and by Treatment (Surgery, Radiation Therapy, Chemotherapy, Stem Cell Therapy) - Forecast Till 2030
ID: MRFR/Pharma/5107-HCR | 100 Pages | Published By Rahul Gotadki on March 2023
Speak to Analyst
Request a Free Sample
Rhabdomyosarcoma Market Scenario The rhabdomyosarcoma market is projected to reach USD 1.74 Billion by 2030 at 3.80% CAGR during the forecast period 2022-2030 .Rhabdomyosarcoma is a type of cancerous tumor that starts to develop in the soft tissues of the body. Cells affected by rhabdomyosarcoma can grow and spread very fast.
Numerous factors such as raising awareness of rhabdomyosarcoma and its increasing prevalence are expected to drive the growth of the market.
Moreover, favorable healthcare investments by government and the rising demand for better treatments boosts the growth of the market. However, stringent government regulation for product approval and huge costs of the treatment may hamper the market growth during the assessment period.
Segmentation
The rhabdomyosarcoma market has been segmented into type, diagnosis, and treatment.
The market, on the basis of type, has been segmented into Embryonal Rhabdomyosarcoma and Alveolar Rhabdomyosarcoma.
The market, by diagnosis, has been segmented into Imaging Tests and Biopsy.
Imaging tests are further segmented into X-Ray, MRI scan, CT scan, PET scan, and Bone Scan.
Biopsy is further segmented into Needle Biopsy and Surgery Biopsy.
The market, by treatment, has been segmented into Surgery, Radiation Therapy, Chemotherapy and Stem Cell Therapy. Chemotherapy is expected to account for the largest market share due to its effective treatment for minimizing the risk of cancer reoccurrence and high preference among the patients. Radiation therapy is anticipated to be the fastest growing segment due to technological advancements in the segment.
The market, by region, has been segmented into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The rhabdomyosarcoma market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European rhabdomyosarcoma market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The rhabdomyosarcoma market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The rhabdomyosarcoma market in the Middle East & Africa has been segmented into the Middle East and Africa.
Key players
Boehringer Ingelheim International GmbH, Pfizer Inc, Eli Lilly & Company, Novartis AG, Bristol Myers Squibb Company, TAIHO ONCOLOGY, INC., Oasmia, Bellicum Pharmaceuticals, Inc., CELGENE CORPORATION, Eisai Co., Ltd., MacroGenics, Inc., NantKwest., Tarveda Therapeutics., Exelixis, Inc., and Ipsen Pharma are some of the key players in the rhabdomyosarcoma market.
Regional Market Summary
Rhabdomyosarcoma Market Share (%), by Region, 2017
Source: World Health Organization (WHO), Centers for Disease Control and Prevention (CDC)
Geographically, the Americas is anticipated to dominate the rhabdomyosarcoma market owing to growing incidences of rhabdomyosarcoma and other soft tissue cancers. According to a report published by The American Cancer Society in July 2018, in the US records approximately 400 to 500 new cases of rhabdomyosarcoma every year. Additionally, government support in this region contributes to the growth of the market.
Europe is expected to hold the second largest position in the rhabdomyosarcoma market. The market growth in this region is attributed to the increasing healthcare expenditure.
Asia-Pacific is anticipated to be the fastest growing region in the market due to the presence of a huge patient population suffering from rhabdomyosarcoma, market players introducing new anticancer molecules in the region and raising awareness about cancer. For instance, in February 2016, Eisai Co., Ltd. received approval for developing its anticancer agent Halaven in Japan. A drug is a treatment option for treating patients suffering from soft tissue sarcomas.
On the other hand, the Middle East & Africa has the lowest market share. Majority of the market of this region is expected to be held by the Middle East region due to rising cases of rhabdomyosarcoma.
Rhabdomyosarcoma Market, by Type
- Embryonal Rhabdomyosarcoma
- Alveolar Rhabdomyosarcoma
Rhabdomyosarcoma Market, by Diagnosis
- Imaging Tests
- X-Ray
- CT Scan
- MRI Scan
- PET Scan
- Bone Scan
- Biopsy
- Needle Biopsy
- Surgical Biopsy
Rhabdomyosarcoma Market, by Treatment
- Surgery
- Radiation Therapy
- Chemotherapy
- Stem Cell Therapy
Rhabdomyosarcoma Market, by Region
-
Americas- North America
- US
- Canada
- South America
-
Europe- Western Europe
- Germany
- France
- Italy
- Spain
- UK
- Rest of Western Europe
- Eastern Europe
-
Asia-Pacific- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
-
Middle East & Africa- Middle East
- Africa
Intended Audience
-
Pharmaceutical Companies
-
Rhabdomyosarcoma Drug Suppliers & Manufacturers
-
Research and Development (R&D) Companies
-
Medical Research Laboratories
-
Government Research Institute
-
Academic Institutes and Universities
Report Scope:
| Report Attribute/Metric | Details |
|---|---|
| Market Size | 2030: USD 1.74 Billion |
| CAGR | 3.80% (2022-2030) |
| Base Year | 2021 |
| Forecast Period | 2022-2030 |
| Historical Data | 2020 |
| Forecast Units | Value (USD Million) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Type, Diagnosis, and Treatment |
| Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
| Key Vendors | Boehringer Ingelheim International GmbH, Pfizer Inc, Eli Lilly & Company, Novartis AG, Bristol Myers Squibb Company, TAIHO ONCOLOGY, INC., Oasmia, Bellicum Pharmaceuticals, Inc., CELGENE CORPORATION, Eisai Co., Ltd., MacroGenics, Inc., NantKwest., Tarveda Therapeutics., Exelixis, Inc., and Ipsen Pharma |
| Key Market Opportunities | New product launches and R&D Amongst major key Players |
| Key Market Drivers | Raising awareness of rhabdomyosarcoma and its increasing prevalence |
Frequently Asked Questions (FAQ) :
Rhabdomyosarcoma Market is projected to grow at a 3.80% CAGR between 2022-2030.
The Americas is projected to command the largest share in Rhabdomyosarcoma Market.
Chemotherapy segment will dominate Rhabdomyosarcoma Market.
Increasing prevalence of rhabdomyosarcoma is boosting market growth.
Huge treatment cost may limit market growth.
